Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17856
Title: Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis.
Authors: Sathianathen, Niranjan J;Kuntz, Karen M;Alarid-Escudero, Fernando;Lawrentschuk, Nathan L;Bolton, Damien M;Murphy, Declan G;Weight, Christopher J;Konety, Badrinath R
Affiliation: Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
Department of Surgery, Urology Unit, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Olivia Newton John Cancer Wellness & Research Centre, Austin Health, Heidelberg, Victoria, Australia
Division of Health Policy & Management, School of Public Health, University of Minnesota, Minneapolis, MN, United States
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Issue Date: 2018
EDate: 2018-06-12
Citation: The Journal of Urology 2018; online first: 12 June
Abstract: To perform a cost-effectiveness analysis of using Prostate Health Index (PHI), 4Kscore, SelectMDx and ExoDx Prostate IntelliScore (EPI) in men with an elevated PSA value to determine the need for biopsy. We developed a decision-analytic model for men with an elevated PSA values (≥ 3ng/mL) where one of the biomarker tests was to determine which hypothetical individuals required a biopsy. In the current standard of care strategy, all individuals underwent a biopsy. Model parameters were derived from a comprehensive review of the literature. Costs were calculated from a health sector perspective and converted into 2017 US dollars. The cost and QALYs of the current standard of care (transrectal ultrasound guided biopsy) was $3,863 and 18.085, respectively. The use of any of the three biomarkers improved quality-adjusted survival compared to the current standard of care. The cost of SelectMDx, PHI and EPI was lower than performing a prostate biopsy on all patients. However, PHI was more costly and less effective than the SelectMDx strategy. EPI provided the highest QALY with an incremental cost-effectiveness ratio of $58,404 per QALY. The use of biomarkers could reduce the number of unnecessary biopsies by 24-34% compared to the current standard of care. The use of biomarkers in men with an elevated PSA to determine the need for biopsy improves quality-adjusted survival by decreasing the number of biopsies performed and treatment of indolent disease. Obtaining a SelectMDx or EPI following an elevated PSA but before proceeding to a biopsy are cost-effective strategies in this setting.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17856
DOI: 10.1016/j.juro.2018.06.016
ORCID: 0000-0001-8553-5618
0000-0002-5145-6783
PubMed URL: 29906434
Type: Journal Article
Subjects: biomarkers
biopsy
cost analysis
cost savings
decision making
prostate cancer
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.